Please login to the form below

Not currently logged in
Email:
Password:

trial failures

This page shows the latest trial failures news and features for those working in and with pharma, biotech and healthcare.

Merck gets first approval for MET inhibitor tepotinib in Japan

Merck gets first approval for MET inhibitor tepotinib in Japan

combination. MET is known as a resistance mechanism for EGFR-positive NSCLC, and Merck also has a trial on the go of tepotinib plus Tagrisso in this setting. ... ArQule and Kyowa Hakko abandoned their MET inhibitor tivantinib in 2017 after a string of

Latest news

More from news
Approximately 5 fully matching, plus 30 partially matching documents found.

Latest Intelligence

  • Alzheimer’s: the search for a cure Alzheimer’s: the search for a cure

    And the timing couldn’t be more auspicious because, after more than two decades of clinical trial failures, there’s good reason to believe we’ll finally see a light at ... However, because of the less advanced trial methodologies used at that point,

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    major trial failures meaning the company was looking unlikely to fill the void created by patent expiries of key drugs.

  • An eye towards the biobetter in South Korea An eye towards the biobetter in South Korea

    Smaller entities such as Isu Abxis are listed companies whose stock prices and financial stability are especially vulnerable to trial failures. ... Some companies already have their biobetter pipelines in clinical trial stage.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
certain health

Transforming the way health brands and companies communicate, we deliver creative science led, insight-driven solutions that give award winning results...

Latest intelligence

Understanding behaviour change: A Porterhouse Insights specialism
...
Robust Review: COVID19 Assessment
See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
Human behaviour - Sept 21
All change – how untangling human behaviour can encourage better health
Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...